NVS
Price
$130.77
Change
+$0.80 (+0.62%)
Updated
Oct 16 closing price
Capitalization
251.96B
11 days until earnings call
Intraday Buy/Sell Signals
RHHBY
Price
$44.67
Change
+$0.19 (+0.43%)
Updated
Oct 16 closing price
Capitalization
285.11B
6 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

NVS vs RHHBY

Header iconNVS vs RHHBY Comparison
Open Charts NVS vs RHHBYBanner chart's image
Novartis AG
Price$130.77
Change+$0.80 (+0.62%)
Volume$1.17M
Capitalization251.96B
Roche Holding
Price$44.67
Change+$0.19 (+0.43%)
Volume$733.2K
Capitalization285.11B
NVS vs RHHBY Comparison Chart in %
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. RHHBY commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Hold and RHHBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (NVS: $130.77 vs. RHHBY: $44.67)
Brand notoriety: NVS and RHHBY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 79% vs. RHHBY: 52%
Market capitalization -- NVS: $251.96B vs. RHHBY: $285.11B
NVS [@Pharmaceuticals: Major] is valued at $251.96B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $285.11B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $734.54B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $93.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 2 FA rating(s) are green whileRHHBY’s FA Score has 2 green FA rating(s).

  • NVS’s FA Score: 2 green, 3 red.
  • RHHBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than RHHBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 2 TA indicator(s) are bullish while RHHBY’s TA Score has 4 bullish TA indicator(s).

  • NVS’s TA Score: 2 bullish, 6 bearish.
  • RHHBY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RHHBY is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а -0.22% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was -1.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.35%. For the same industry, the average monthly price growth was +2.29%, and the average quarterly price growth was +20.68%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

RHHBY is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.35% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($285B) has a higher market cap than NVS($252B). RHHBY has higher P/E ratio than NVS: RHHBY (24.40) vs NVS (19.06). NVS YTD gains are higher at: 39.223 vs. RHHBY (32.326). NVS has higher annual earnings (EBITDA): 22.7B vs. RHHBY (18B). RHHBY has more cash in the bank: 12B vs. NVS (7B). NVS (32.6B) and RHHBY (33B) have identical debt. RHHBY has higher revenues than NVS: RHHBY (63.5B) vs NVS (55.2B).
NVSRHHBYNVS / RHHBY
Capitalization252B285B88%
EBITDA22.7B18B126%
Gain YTD39.22332.326121%
P/E Ratio19.0624.4078%
Revenue55.2B63.5B87%
Total Cash7B12B58%
Total Debt32.6B33B99%
FUNDAMENTALS RATINGS
NVS vs RHHBY: Fundamental Ratings
NVS
RHHBY
OUTLOOK RATING
1..100
7117
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
13
Undervalued
PROFIT vs RISK RATING
1..100
1377
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4747
P/E GROWTH RATING
1..100
4727
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RHHBY's Valuation (13) in the null industry is in the same range as NVS (15) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (77) in the null industry. This means that NVS’s stock grew somewhat faster than RHHBY’s over the last 12 months.

NVS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as RHHBY (100) in the null industry. This means that NVS’s stock grew similarly to RHHBY’s over the last 12 months.

NVS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as RHHBY (47) in the null industry. This means that NVS’s stock grew similarly to RHHBY’s over the last 12 months.

RHHBY's P/E Growth Rating (27) in the null industry is in the same range as NVS (47) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSRHHBY
RSI
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 1 day ago
55%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 1 day ago
53%
Momentum
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
47%
MACD
ODDS (%)
Bearish Trend 1 day ago
47%
Bullish Trend 1 day ago
54%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
42%
Bearish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 1 day ago
51%
Advances
ODDS (%)
Bullish Trend 17 days ago
50%
Bullish Trend 8 days ago
52%
Declines
ODDS (%)
Bearish Trend 5 days ago
44%
Bearish Trend 3 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
41%
Bearish Trend 1 day ago
42%
Aroon
ODDS (%)
Bullish Trend 1 day ago
45%
Bullish Trend 1 day ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IEF97.550.45
+0.46%
iShares 7-10 Year Treasury Bond ETF
GF11.330.04
+0.35%
NEW Germany Fund
DUKZ25.63N/A
+0.02%
Ocean Park Diversified Income ETF
AAA25.01-0.01
-0.06%
Alternative AccessFirstPriorityCLO BdETF
IXP121.95-0.26
-0.21%
iShares Global Comm Services ETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.62%
GSK - NVS
69%
Closely correlated
-0.02%
AZN - NVS
62%
Loosely correlated
-1.18%
PFE - NVS
60%
Loosely correlated
-0.66%
JNJ - NVS
54%
Loosely correlated
+0.50%
SNY - NVS
50%
Loosely correlated
+2.17%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
+0.43%
RHHVF - RHHBY
65%
Loosely correlated
+3.06%
NVS - RHHBY
37%
Loosely correlated
+0.62%
JNJ - RHHBY
37%
Loosely correlated
+0.50%
RHHBF - RHHBY
32%
Poorly correlated
+3.00%
BMY - RHHBY
28%
Poorly correlated
-0.50%
More